Literature DB >> 17908533

Central nervous system tumors.

Jan C Buckner1, Paul D Brown, Brian P O'Neill, Frederic B Meyer, Cynthia J Wetmore, Joon H Uhm.   

Abstract

Central nervous system tumors are relatively common in the United States, with more than 40,000 cases annually. Although more than half of these tumors are benign, they can cause substantial morbidity. Malignant primary brain tumors are the leading cause of death from solid tumors in children and the third leading cause of death from cancer in adolescents and adults aged 15 to 34 years. Common presenting symptoms include headache, seizures, and altered mental status. Whereas magnetic resonance imaging helps define the anatomic extent of tumor, biopsy is often required to confirm the diagnosis. Treatment depends on the histologic diagnosis. Benign tumors are usually curable with surgical resection or radiation therapy including stereotactic radiation; however, most patients with malignant brain tumors benefit from chemotherapy either at the time of initial diagnosis or at tumor recurrence. Metastases to the brain remain a frequent and morbid complication of solid tumors but are frequently controlled with surgery or radiation therapy. Unfortunately, the mortality rate from malignant brain tumors remains high, despite initial disease control. This article provides an overview of current diagnostic and treatment approaches for patients with primary and metastatic brain tumors.

Entities:  

Mesh:

Year:  2007        PMID: 17908533     DOI: 10.4065/82.10.1271

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  93 in total

1.  A study of patients with brain metastases as the initial manifestation of their systemic cancer in a Chinese population.

Authors:  Jia Jin; Xinli Zhou; Xiaohua Liang; Ruofan Huang; Zhaohui Chu; Jingwei Jiang; Qiong Zhan
Journal:  J Neurooncol       Date:  2010-10-27       Impact factor: 4.130

2.  Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche.

Authors:  David W Infanger; YouJin Cho; Brina S Lopez; Sunish Mohanan; S Chris Liu; Demirkan Gursel; John A Boockvar; Claudia Fischbach
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

3.  Mis-trafficking of endosomal urokinase proteins triggers drug-induced glioma nonapoptotic cell death.

Authors:  Nagarekha Pasupuleti; Ana Cristina Grodzki; Fredric Gorin
Journal:  Mol Pharmacol       Date:  2015-01-29       Impact factor: 4.436

4.  Working memory and the identification of facial expression in patients with left frontal glioma.

Authors:  Yong-Gao Mu; Ling-Juan Huang; Shi-Yun Li; Chao Ke; Yu Chen; Yu Jin; Zhong-Ping Chen
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

5.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

Authors:  Shaji K Kumar; Joseph R Mikhael; Francis K Buadi; David Dingli; Angela Dispenzieri; Rafael Fonseca; Morie A Gertz; Philip R Greipp; Suzanne R Hayman; Robert A Kyle; Martha Q Lacy; John A Lust; Craig B Reeder; Vivek Roy; Stephen J Russell; Kristen E Detweiler Short; A Keith Stewart; Thomas E Witzig; Steven R Zeldenrust; Robert J Dalton; S Vincent Rajkumar; P Leif Bergsagel
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

6.  5-Benzylglycinyl-amiloride kills proliferating and nonproliferating malignant glioma cells through caspase-independent necroptosis mediated by apoptosis-inducing factor.

Authors:  Nagarekha Pasupuleti; Leonardo Leon; Kermit L Carraway; Fredric Gorin
Journal:  J Pharmacol Exp Ther       Date:  2012-12-14       Impact factor: 4.030

7.  Bex2 is critical for migration and invasion in malignant glioma cells.

Authors:  Xiuping Zhou; Xuebin Xu; Qingming Meng; Jinxia Hu; Tongle Zhi; Qiong Shi; Rutong Yu
Journal:  J Mol Neurosci       Date:  2012-08-03       Impact factor: 3.444

Review 8.  Brain tumor stem cells as therapeutic targets in models of glioma.

Authors:  Dan Richard Laks; Koppany Visnyei; Harley Ian Kornblum
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 2.759

9.  Ubiquitin-specific protease 22: a novel molecular biomarker in glioma prognosis and therapeutics.

Authors:  Jun Liang; Xianli Zhang; Shao Xie; Xiuping Zhou; Qiong Shi; Jinxia Hu; Weifeng Wang; Weifeng Qi; Rutong Yu
Journal:  Med Oncol       Date:  2014-02-27       Impact factor: 3.064

10.  Therapeutic vaccines for malignant brain tumors.

Authors:  Michael P Gustafson; Keith L Knutson; Allan B Dietz
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.